Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 27,778 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 2 Interventional Results available

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

NCT02443688
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CTX-4430, Placebo
Drug
Lead sponsor
Celtaxsys, Inc.
Other
Eligibility
18 Years to 30 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
39
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Results available

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

NCT01082588
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
Interventions
Pravastatin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Airway Alkalinization and Nasal Colonization

NCT03078088
View directory record Official record
Conditions
Healthy Subjects, Cystic Fibrosis
Interventions
Tham, Saline
Drug
Lead sponsor
Lakshmi Durairaj
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01038427
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

NCT00415142
View directory record Official record
Conditions
Depressive Disorder
Interventions
saredutant (SR48968), placebo, escitalopram
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years to 64 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Saracatinib and Alcohol Drinking

NCT02955186
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Saracatinib, Placebos
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Results available

Niacin and Endothelial Function in Early CKD

NCT00852969
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Niacin, Active Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 21, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

NCT06996652
View directory record Official record
Conditions
REM Sleep Behavior Disorder
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
50 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

NCT03732833
View directory record Official record
Conditions
Lateral Canthal Lines, Glabellar Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 21, 2026, 2:43 AM EDT
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

NCT00577148
View directory record Official record
Conditions
Fatty Liver
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

NCT02963935
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo, CMS Intensive Behavior Therapy
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Jacksonville, Florida • Plantation, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 21, 2026, 2:43 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

NCT07119125
View directory record Official record
Conditions
Healthy Volunteers, Elevated CRP
Interventions
MRT-8102, Placebo
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 2:43 AM EDT
Active, not recruiting Phase 2 Interventional

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

NCT04060017
View directory record Official record
Conditions
Autism Spectrum Disorder, Language Disorders
Interventions
Levoleucovorin Calcium, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
30 Months to 60 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 4 Interventional

ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF

NCT05152940
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Congestion
Interventions
Ertugliflozin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

NCT00103740
View directory record Official record
Conditions
Paget's Disease of Bone
Interventions
zoledronic acid, placebo to zoledronic acid, Risedronate, Placebo to risedronate, Calcium and vitamin D supplements
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
10
States / cities
Tucson, Arizona • Colorado Springs, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Results available

Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

NCT02328040
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo and Insulin monotherapy via CL, Sitagliptin and insulin/novolog via CL
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
14 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091
View directory record Official record
Conditions
Long COVID
Interventions
Nirmatrelvir, Ritonavir, Placebo
Drug
Lead sponsor
Harlan M Krumholz
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 21, 2026, 2:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Microarray Analysis of Scalp Biopsies After Minoxidil Treatment

NCT01309191
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Minoxidil, Placebo
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 21, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

NCT04980391
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 49 Years · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 21, 2026, 2:43 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

NCT05988710
View directory record Official record
Conditions
Analgesia, Abuse Opioids, Pain
Interventions
Buccal Buprenorphine 300 mcg, Buccal Buprenorphine 600 mcg, Buccal Buprenorphine 900 mcg, Buccal Placebo, Oral Placebo, Oral immediate-release oxycodone 10mg, Buccal Buprenorphine 450mcg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 21, 2026, 2:43 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02824913
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 21, 2026, 2:43 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma

NCT00590720
View directory record Official record
Conditions
Asthma
Interventions
MEDI528 50 mg, PLACEBO
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Waterbury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 21, 2026, 2:43 AM EDT